JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Eli Lilly and Co.

Затворен

СекторЗдравеопазване

795.48 0.43

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

785.34

Максимум

798.46

Ключови измерители

By Trading Economics

Приходи

-6.1B

2.8B

Продажби

-804M

13B

P/E

Средно за сектора

62.756

50.291

EPS

3.34

Дивидентна доходност

0.79

Марж на печалбата

21.678

Служители

47,000

EBITDA

-2B

4.2B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+26.16% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.79%

2.40%

Следващи печалби

6.08.2025 г.

Следваща дата на дивидент

10.09.2025 г.

Следваща дата на екс-дивидент

15.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-136B

692B

Предишно отваряне

795.05

Предишно затваряне

795.48

Настроения в новините

By Acuity

38%

62%

125 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.06.2025 г., 11:56 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27.05.2025 г., 14:41 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17.06.2025 г., 14:02 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17.06.2025 г., 12:12 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17.06.2025 г., 11:01 ч. UTC

Придобивния, сливания и поглъщания

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17.06.2025 г., 10:47 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17.06.2025 г., 10:47 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17.06.2025 г., 10:46 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17.06.2025 г., 10:45 ч. UTC

Придобивния, сливания и поглъщания

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17.06.2025 г., 09:33 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11.06.2025 г., 09:45 ч. UTC

Пазарно говорене

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29.05.2025 г., 01:00 ч. UTC

Топ новини

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New -2-

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27.05.2025 г., 14:02 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27.05.2025 г., 14:01 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27.05.2025 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27.05.2025 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20.05.2025 г., 14:08 ч. UTC

Печалби

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 17:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7.05.2025 г., 17:01 ч. UTC

Топ новини

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7.05.2025 г., 13:56 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7.05.2025 г., 11:18 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7.05.2025 г., 09:30 ч. UTC

Топ новини

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6.05.2025 г., 20:30 ч. UTC

Топ новини

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4.05.2025 г., 04:05 ч. UTC

Придобивния, сливания и поглъщания

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1.05.2025 г., 21:07 ч. UTC

Пазарно говорене

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1.05.2025 г., 14:07 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

26.16% нагоре

12-месечна прогноза

Среден 999.57 USD  26.16%

Висок 1,190 USD

Нисък 700 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

16

Купи

2

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 884.54Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

125 / 380 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.